ID: MRFR/Pharma/1967-HCR | 55 Pages | Author: Rahul Gotadki | September 2023
Study objectives of Middle-East and Africa Hypertension Drugs Market:
Middle-East and Africa Hypertension Drugs Market by Type
Intended Audience
Market Synopsis of Middle-East and Africa Hypertension Drugs Market:
Market Scenario:
The Middle-East and Africa Hypertension Drugs Market is projected to reach USD 6,985.6 Million by 2030 at 6.1% CAGR during the forecast period 2022-2030. Hypertension or high blood pressure is the condition when blood pressure increases to the unhealthy level. Hypertension is very harmful and it can lead to stroke, heart failure, heart attack and kidney diseases. The main purpose of anti-hypertension drug is to lower and control high blood pressure to protect organs like brain, heart, kidneys. Hypertension affects four out of ten adults in Middle East and Africa region. Over 1.5 million deaths occurs due to hypertension in Middle East and Africa. Countries in Middle East and Africa bear a heavy burden from hypertension diagnosis and treatment. Huge funding in R&D and various initiatives by government are driving the growth for Hypertension Drugs Market in Middle East and Africa.
Segments:
Middle-East and Africa Hypertension Drugs Market has been segmented on the basis of type which comprise Thiazide diuretics, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Calcium channel blockers, Renin inhibitors, Alpha blockers, Alpha-beta blockers, Central-acting agents, Vasodilators, Aldosterone antagonists, and others.
Regional Analysis of Middle-East and Africa Hypertension Drugs Market:
Considering the Middle-East and Africa Hypertension Drugs Market scenario, UAE region is believed to be the largest market for Middle-East and Africa Hypertension Drugs. Moreover Saudi Arabia market is also growing and second largest market for Hypertension Drugs. On the other hand, Egypt market is expected to grow at the steady pace in the Middle-East and Africa Hypertension Drugs during the forecasted period. Rest of the Middle East and Africa region is likely to have a limited but steady growth in the market.
Key Players for Middle-East and Africa Hypertension Drugs Market:
Some of the key players in this market are: Abbott (US), Johnson & Johnson Services, Inc. (US), Novartis (Switzerland), GlaxoSmithKline plc.(UK), AstraZeneca (UK), Bayer AG (Germany), Pfizer Inc.(US), Merck & Co., Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US)
The report for Middle-East and Africa Hypertension Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Report Attribute/Metric | Details |
---|---|
Market Size | 6,985.6 Million |
CAGR | 6.1% |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type |
Geographies Covered | UAE, Saudi Arabia, Egypt |
Key Vendors | Abbott (US), Johnson & Johnson Services, Inc. (US), Novartis (Switzerland), GlaxoSmithKline plc.(UK), AstraZeneca (UK), Bayer AG (Germany), Pfizer Inc.(US), Merck & Co., Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US) |
Key Market Opportunities | Joint ventures, strategic alliances, mergers and acquisitions, new product developments |
Key Market Drivers | technological advancement, macro economical and governing factors |
Global Middle East and Africa Hypertension Drugs Market is projected to grow at a 6.1% CAGR between 2022-2030
Global Middle East and Africa Hypertension Drugs Market is predicted to touch USD 6,985.6 Million by 2030.
The UAE is predicted to dominate the Middle East and Africa Hypertension Drugs Market.
Various government initiatives and huge funding in research and development are boosting market growth.
Key competitors in the Middle East and Africa Hypertension Drugs Market include Gilead (US), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Merck & Co., Inc. (US), Pfizer Inc. (US), Bayer AG (Germany), GlaxoSmithKline plc. (UK), AstraZeneca (UK), Novartis (Switzerland), Johnson & Johnson Services, Inc. (US), and Abbott (US).
Key Questions Answered
Why Choose Market Research Future?